BMW’s first-quarter operating profit fell 78% to €589 million (US$658.4 million), reported Reuters. This was not helped by BMW being compelled to set aside €1.4 billion (US$1.6 billion) to cover a possible fine from EU antitrust authorities.
The European Commission last month told German carmakers they face hefty fines for alleged collusion in the area of emissions filtering technology. BMW denies participating in antitrust activities and is contesting the allegations.
BMW’s first-quarter earnings before interest and taxes were below the €666 million (US$744.3 million) forecast in an analyst poll. A contribution of €648 million (US$724.2 million) from financial services only partially offset a €310 million (US$346.5 million) loss before interest and taxes at the automotive division.
Analysts said BMW’s results were underwhelming; “As most companies have done, BMW points towards a stronger second half this year. We remain skeptical regarding this optimism as we don’t see much stronger end-markets,” analysts at Evercore ISI said, citing trade tensions and emissions rules as risks.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation Monopoly
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan